Strategic US expansion Diabeloop is preparing a major market expansion into the US in 2026 through strategic partnerships with Sequel Med Tech and ongoing FDA clearance activity for DBLG2. Sales opportunities include partnering with US-based distributors, securing payer coverage discussions, and aligning with hospital systems and diabetes centers to showcase DBLG2 interoperability with Dexcom G7.

Interoperable AID platform DBLG2 offers interoperability with Dexcom CGMs and potential integration with multiple insulin pumps, presenting a strong selling point for clinics seeking flexible automated insulin delivery solutions. Focus on hospital systems and clinics that require adaptable tech stacks and seamless data integration for diabetes management programs.

Regulatory momentum Recent CE marking and FDA 510(k) clearance for DBLG2, plus European rollout and upcoming US availability, create a favorable buying environment. Emphasize regulatory milestones to reassure procurement teams about product legitimacy, payer acceptance, and long-term support.

Clinical performance focus The platform targets improved Time in Range and reduced hypoglycemia, addressing core outcomes valued by endocrinologists and diabetes centers. Sales pitches should highlight clinical data, patient burden reduction, and case studies that demonstrate real-world effectiveness in diverse patient populations.

Global growth traction With a global investor-backed trajectory and over 70 employees, Diabeloop is scaling operations to support international partnerships and deployments. Opportunities exist in channel partnerships, professional services, and training programs to accelerate adoption in new markets and ensure successful implementations.